In dermatology, Björklund Pharma introduces InBio Paeonol + Zinc, a dermatological ointment formulated with natural ingredients for managing inflammatory skin conditions, and thymosin beta 4, a promising candidate with well-understood mechanisms, an excellent safety profile, and observed efficacy in reducing healing time. Both of these products represent innovative solutions in dermatological care.
Product Candidates
InBio Paeonol + Zinc
InBio Paeonol + Zinc is a dermatological ointment formulated with natural ingredients renowned for their therapeutic efficacy in managing inflammatory skin conditions. The product includes paeonol extract, zinc oxide, aloe vera gel, shea butter, and olive oil. Paeonol, derived from Paeonia suffruticosa, possesses potent anti-inflammatory and antioxidant properties that help soothe and reinforce the skin barrier, making it particularly beneficial for eczema and dermatitis.
Zinc oxide is known for its antimicrobial and wound-healing effects, supporting skin regeneration and reducing redness and discomfort associated with inflammatory conditions. Aloe vera gel hydrates the skin, accelerates wound healing, and alleviates itching and irritation. Shea butter nourishes and fortifies the skin’s natural barrier, ideal for dry and sensitive skin types. Olive oil shields and replenishes the skin, enhancing elasticity and supporting repair processes.
The synergistic action of these natural ingredients in InBio Paeonol + Zinc offers a holistic approach to calming and fortifying inflamed skin. This formulation is suitable for individuals affected by eczema, dermatitis, or pruritus, providing gentle yet effective relief for sensitive and irritated skin. For topical application, apply a thin layer to affected areas and gently massage until absorbed, avoiding contact with eyes or mucous membranes. If skin irritation occurs, discontinue use and consult with a healthcare professional.
Store this product at room temperature, away from light and moisture, to preserve its integrity and efficacy.
Thymosin Beta 4 in Dermal Healing
Unlike many pharmacological treatments for various pathologies, much is known about the mechanisms of action of thymosin beta 4 (Tβ4). The active site(s), receptor, signaling pathways, and biological activities are known. The safety profile is excellent, and no preclinical toxicology has been found (1).
Efficacy trends have been observed in phase 2 clinical trials, which reduced the healing time by almost half. Also, a near-optimal dose (0.02–0.03%, w/w) has been identified in dosing studies for dermal healing. Finally, no adverse reactions have been observed with topical or injected Tβ4 in humans, and no autoantibodies have been detected. Tβ4 is a naturally occurring molecule that relatively cheaply can be synthesized. The cost is important given that other treatments are not widely used due to the high cost and limited efficacy (1).
Reference
- Kleinman HK, Sosne G. Thymosin β4 promotes dermal healing. Vitam Horm 2016;102:251-75. doi: 10.1016/bs.vh.2016.04.005.